- Home
- GOF vs MIRM Comparison
GOF vs MIRM Comparison
Compare GOF & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOF
- MIRM
- Stock Information
- Founded
- GOF 2006
- MIRM 2018
- Country
- GOF United States
- MIRM United States
- Employees
- GOF N/A
- MIRM N/A
- Industry
- GOF Finance/Investors Services
- MIRM Biotechnology: Pharmaceutical Preparations
- Sector
- GOF Finance
- MIRM Health Care
- Exchange
- GOF Nasdaq
- MIRM Nasdaq
- Market Cap
- GOF 2.4B
- MIRM 2.2B
- IPO Year
- GOF N/A
- MIRM 2019
- Fundamental
- Price
- GOF $14.55
- MIRM $50.34
- Analyst Decision
- GOF
- MIRM Strong Buy
- Analyst Count
- GOF 0
- MIRM 12
- Target Price
- GOF N/A
- MIRM $63.17
- AVG Volume (30 Days)
- GOF 789.2K
- MIRM 426.0K
- Earning Date
- GOF 01-01-0001
- MIRM 08-06-2025
- Dividend Yield
- GOF 15.42%
- MIRM N/A
- EPS Growth
- GOF N/A
- MIRM N/A
- EPS
- GOF N/A
- MIRM N/A
- Revenue
- GOF N/A
- MIRM $379,251,000.00
- Revenue This Year
- GOF N/A
- MIRM $35.83
- Revenue Next Year
- GOF N/A
- MIRM $16.83
- P/E Ratio
- GOF N/A
- MIRM N/A
- Revenue Growth
- GOF N/A
- MIRM 69.31
- 52 Week Low
- GOF $10.96
- MIRM $28.56
- 52 Week High
- GOF $16.76
- MIRM $54.23
- Technical
- Relative Strength Index (RSI)
- GOF 44.27
- MIRM 69.78
- Support Level
- GOF $14.47
- MIRM $48.78
- Resistance Level
- GOF $14.66
- MIRM $50.05
- Average True Range (ATR)
- GOF 0.13
- MIRM 1.64
- MACD
- GOF -0.03
- MIRM 0.39
- Stochastic Oscillator
- GOF 16.67
- MIRM 87.92
About GOF Guggenheim Strategic Opportunities Fund of Beneficial Interest
Guggenheim Strategic Opportunities Fund is a diversified, closed-end management investment company. The investment objective of the firm is to maximize total return through a combination of current income and capital appreciation. The Fund seeks to combine a credit-managed fixed-income portfolio with access to a diversified pool of alternative investments and equity strategies.
About MIRM Mirum Pharmaceuticals Inc.
Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.